Astria Therapeutics (NASDAQ:ATXS) Releases Quarterly Earnings Results, Misses Estimates By $0.05 EPS

Astria Therapeutics (NASDAQ:ATXS) announced its earnings results on Monday. The biotechnology company reported ($0.43) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.05), Yahoo Finance reports.

Astria Therapeutics Stock Up 7.5 %

ATXS opened at $10.49 on Wednesday. Astria Therapeutics has a 52 week low of $4.26 and a 52 week high of $16.90. The business has a fifty day simple moving average of $10.06 and a 200-day simple moving average of $11.38. The firm has a market cap of $576.04 million, a P/E ratio of -4.52 and a beta of 0.73.

Analyst Ratings Changes

Several research firms recently commented on ATXS. Oppenheimer increased their price target on Astria Therapeutics from $25.00 to $26.00 and gave the company an “outperform” rating in a report on Tuesday. HC Wainwright reaffirmed a “buy” rating and issued a $16.00 price target on shares of Astria Therapeutics in a report on Tuesday. TD Cowen began coverage on Astria Therapeutics in a report on Monday, July 29th. They issued a “buy” rating and a $35.00 price target for the company. Finally, Wedbush reaffirmed an “outperform” rating and issued a $22.00 price target on shares of Astria Therapeutics in a report on Tuesday. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $25.20.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.